TriSalus Life Sciences (NASDAQ:TLSI) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS

TriSalus Life Sciences (NASDAQ:TLSI) issued its quarterly earnings data on Tuesday. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02), FiscalAI reports. The business had revenue of $12.88 million during the quarter, compared to the consensus estimate of $14.02 million.

Here are the key takeaways from TriSalus Life Sciences’ conference call:

• Negative sentiment: Third-quarter revenue rose 11% year over year to $12.9 million, but growth was below expectations. TriSalus lowered its 2026 revenue outlook to $46 million–$48 million, or 2%–6% growth, citing slower productivity in new sales territories and a shift toward super-selective Y90 procedures.
• Positive sentiment: FDA clearance of TriNav Advance extends the company’s technology to small distal vessels, addressing procedures it previously could not fully serve. A limited release is underway; management said the product is not included in fourth-quarter revenue guidance.
• Positive sentiment: CMS finalized higher 2027 Medicare payment for Y90 mapping procedures and national pricing of about $13,788 for PEDD procedures in office-based labs. Management expects the changes to strengthen reimbursement and expand access across care settings.
• Positive sentiment: Gross margin improved to 86%, adjusted EBITDA loss narrowed to $4.7 million, and the company ended the quarter with about $41 million in cash, which management said funds its strategic growth plan.
• Neutral sentiment: TriSalus reported 11 active studies across 27 clinical sites and plans to advance comparative studies in liver cancer segments, alongside research in other indications. Upcoming evidence and publications could support adoption, though many milestones remain prospective.

TriSalus Life Sciences Trading Down 19.3%

Shares of TLSI traded down $0.62 during mid-day trading on Tuesday, reaching $2.60. 881,118 shares of the company’s stock traded hands, compared to its average volume of 291,440. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. The stock’s 50-day moving average is $4.25 and its two-hundred day moving average is $4.35. TriSalus Life Sciences has a 12 month low of $2.20 and a 12 month high of $7.95. The stock has a market cap of $160.11 million, a P/E ratio of -2.01 and a beta of 0.50.

Wall Street Analysts Forecast Growth

TLSI has been the subject of a number of recent research reports. Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a report on Thursday, September 10th. Stifel Nicolaus set a $12.00 target price on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Wednesday, November 4th. Guggenheim set a $12.00 price target on TriSalus Life Sciences in a research report on Wednesday, September 23rd. Finally, HC Wainwright lifted their price objective on shares of TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.20.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences is an oncology-focused healthcare company developing technologies and therapies for patients with liver and pancreatic tumors. The company combines medical devices, drug-delivery systems and immunotherapy programs to address tumors that may be difficult to treat with conventional approaches.

Its core technology is Pressure-Enabled Drug Delivery (PEDD), a platform designed to improve the delivery of therapeutic agents directly to tumors through the arterial blood supply.